



Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference

November 13, 2024

BOSTON--(BUSINESS WIRE)--Nov. 13, 2024-- [Astria Therapeutics, Inc.](#) (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies London Healthcare Conference on Wednesday, November 20th at 12:00pm GMT in London, UK.

A webcast of the presentation can be accessed at the following link: <https://wsw.com/webcast/jeff315/atxs/1873536>. An archived replay of the presentation will be available in the investors section of www.astriatx.com for 30 days following the event.

About Astria Therapeutics:

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Our lead program, navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com, or follow us on X and Instagram @AstriaTx and on Facebook and LinkedIn.

View source version on [businesswire.com](https://www.businesswire.com): <https://www.businesswire.com/news/home/20241113458379/en/>

Astria:

Investor Relations and Media:

Elizabeth Higgins

investors@astriatx.com

Source: Astria Therapeutics, Inc.